A Vaccine for the Whole World

A Vaccine for the Whole World

Fantastic news for everyone as a vaccine that Symbiosis has supported is hailed as a “vaccine for the whole world”. #Oxford #AstraZeneca #COVID19 #vaccine has 70.4% average efficacy and 90% if a lower dose used – plus it can be stored at normal fridge temperature (2-8 °C).
Symbiosis is proud of its support for the AstraZeneca clinical trials of the AZD1222 vaccine. Part of a world-class team that is leading – and hopefully winning – the global fight against COVID-19. You can read about our involvement here: https://www.symbiosis-pharma.com/news/symbiosis-astrazeneca-sign-supply-agreement-sterile-manufacture-covid-19-vaccine-clinical-trials/

Details from The University of Oxford’s, and AstraZeneca plc, interim trial data from its Phase III trials show its candidate vaccine, ChAdOx1 nCoV-2019 (AZD1222) is effective at preventing COVID-19 and offers a high level of protection.

Professor Sarah Gilbert, Professor of Vaccinology at the University of Oxford, said there were: “Benefits for the whole world”. Read more details about the trial results here: https://www.ox.ac.uk/news/2020-11-23-oxford-university-breakthrough-global-covid-19-vaccine?hp#

#oxford #astrazeneca #COVID19 #vaccine

Sign up to our Newsletter

Fill in your details to be added to our mailing list and receive our latest updates.